Elena Trombetta

Dr. Elena Trombetta

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
DPDaniela Pollutri
Daniela Pollutri
CPClarissa Patrizi
Clarissa Patrizi
SMSara Marinelli
Sara Marinelli
CGCatia Giovannini
Catia Giovannini
ETElena Trombetta
Elena Trombetta
FFFrancesca Fornari
Francesca Fornari
Hepatocellular carcinoma (HCC) represents the second cause of cancer-related mortality worldwide and is associated with poor prognosis, especially in patients not amenable for curative treatments. The multi-kinase inhibitor sorafenib represents the first-line treatment option for advanced HCC; nevertheless, its effectiveness is limited due to tumor heterogeneity as well as innate or acquired drug resistance, raising the need for new therapeutic strategies. MicroRNAs (miRNAs) involvement in treatment response as well as their safety and efficacy in preclinical models and clinical trials have been widely documented in the oncologic field, including HCC. Here, we identified miR-494 upregulation in a subgroup of human and rat HCCs with stem cell-like characteristics, as well as multiple epigenetic mechanisms involved in its aberrant expression in HCC cell lines and patients. Moreover, we identified p27, puma and pten among miR-494 targets, contributing to speed up cell cycle progression, enhance survival potential in stressful conditions and increase invasive and clonogenic capabilities. MiR-494 overexpression increased sorafenib resistance via mTOR pathway activation in HCC cell lines and, in line, high miR-494 levels associated with decreased sorafenib response in two HCC animal models. A sorafenib-combined anti-miR-494-based strategy revealed an enhanced anti-tumor potential with respect to sorafenib-only treatment in our HCC rat model. In conclusion, our findings suggested miR-494 as a possible therapeutic target as well as a candidate biomarker for patient stratification in advanced HCC.

1 April 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MKMaarten van der Kroef
Maarten van der Kroef
MCMonica Castellucci
Monica Castellucci
MMMichal Mokry
Michal Mokry
MCMarta Cossu
Marta Cossu
MGMarianna Garonzi
Marianna Garonzi
MRMarzia Rossato
Marzia Rossato
Background and objective Systemic sclerosis (SSc) is a severe autoimmune disease, in which the pathogenesis is dependent on both genetic and epigenetic factors. Altered gene expression in SSc monocytes, particularly of interferon (IFN)-responsive genes, suggests their involvement in SSc development. We investigated the correlation between epigenetic histone marks and gene expression in SSc monocytes. Methods Chromatin immunoprecipitation followed by sequencing (ChIPseq) for histone marks H3K4me3 and H3K27ac was performed on monocytes of nine healthy controls and 14 patients with SSc. RNA sequencing was performed in parallel to identify aberrantly expressed genes and their correlation with the levels of H3K4me3 and H3K27ac located nearby their transcription start sites. ChIP-qPCR assays were used to verify the role of bromodomain proteins, H3K27ac and STATs on IFN-responsive gene expression. Results 1046 and 534 genomic loci showed aberrant H3K4me3 and H3K27ac marks, respectively, in SSc monocytes. The expression of 381 genes was directly and significantly proportional to the levels of such chromatin marks present near their transcription start site. Genes correlated to altered histone marks were enriched for immune, IFN and antiviral pathways and presented with recurrent binding sites for IRF and STAT transcription factors at their promoters. IFNα induced the binding of STAT1 and STAT2 at the promoter of two of these genes, while blocking acetylation readers using the bromodomain BET family inhibitor JQ1 suppressed their expression. Conclusion SSc monocytes have altered chromatin marks correlating with their IFN signature. Enzymes modulating these reversible marks may provide interesting therapeutic targets to restore monocyte homeostasis to treat or even prevent SSc.

1 February 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
Alessandro LoglioAlessandro Loglio
Alessandro Loglio
PFPeter Ferenci
Peter Ferenci
SRSara Colonia Uceda Renteria
Sara Colonia Uceda Renteria
CTChristine Y.L. Tham
Christine Y.L. Tham
Caroline ScholtesCaroline Scholtes
Caroline Scholtes
PLPietro Lampertico
Pietro Lampertico

1 October 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
Alessandro LoglioAlessandro Loglio
Alessandro Loglio
PFPeter Ferenci
Peter Ferenci
SRSara Colonia Uceda Renteria
Sara Colonia Uceda Renteria
CTChristine Y.L. Tham
Christine Y.L. Tham
FBFlorian van Bömmel
Florian van Bömmel
PLPietro Lampertico
Pietro Lampertico

1 November 2016 in Autoimmunity Reviews
Verified
Journal Article
Closed access
CJChristophe Jamin
Christophe Jamin
LLLucas Le Lann
Lucas Le Lann
DADamiana Alvarez-Errico
Damiana Alvarez-Errico
NBNuria Barbarroja
Nuria Barbarroja
Tineke CANTAERTTineke CANTAERT
Tineke CANTAERT
JPJacques-Olivier Pers
Jacques-Olivier Pers

22 July 2024 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
CVChiara Villa
Chiara Villa
VSvaleria secchi
valeria secchi
MMMirco Macchi
Mirco Macchi
LTLuana Tripodi
Luana Tripodi
ETElena Trombetta
Elena Trombetta
YTYvan Torrente
Yvan Torrente
Exosomes are promising therapeutics for tissue repair and regeneration to induce and guide appropriate immune responses in dystrophic pathologies. However, manipulating exosomes to control their biodistribution and targeting them in vivo to achieve adequate therapeutic benefits still poses a major challenge. Here we overcome this limitation by developing an externally controlled delivery system for primed annexin A1 myo-exosomes (Exomyo). Effective nanocarriers are realized by immobilizing the Exomyo onto ferromagnetic nanotubes to achieve controlled delivery and localization of Exomyo to skeletal muscles by systemic injection using an external magnetic field. Quantitative muscle-level analyses revealed that macrophages dominate the uptake of Exomyo from these ferromagnetic nanotubes in vivo to synergistically promote beneficial muscle responses in a murine animal model of Duchenne muscular dystrophy. Our findings provide insights into the development of exosome-based therapies for muscle diseases and, in general, highlight the formulation of effective functional nanocarriers aimed at optimizing exosome biodistribution.